Exclusive: KKR, Warburg Pincus group submitted non-binding bid for Gerresheimer, sources say
A consortium including KKR and Warburg Pincus has submitted a non-binding bid for Gerresheimer AG , which makes pens used to inject weight loss drugs like Wegovy, two people with knowledge of the matter said.
FS KKR Capital: Buy The Drop, Lock In A 13% Yield
FS KKR Capital offers high dividend income and upside revaluation potential, trading at only a slight premium to its 3-year average P/NAV ratio. I rate FS KKR Capital a strong buy due to its potential to move towards healthier balance sheet quality and lower its non-accrual percentage. FS KKR Capital under-earned its regular dividend with NII in the last quarter as its non-accrual percentage increased slightly Q/Q.
Warburg Pincus, KKR in talks to buy medical packaging maker Gerresheimer, Bloomberg News reports
A consortium consisting of Warburg Pincus and KKR are in talks to acquire German medical packaging maker Gerresheimer AG , Bloomberg News reported on Wednesday citing people familiar with the matter.
Trade Tracker: Bryn Talking buys KKR and Apollo
Bryn Talkington, Managing Partner of Requisite Capital Management, joins CNBC's "Halftime Report" to explain why she's buying these stocks after they've fallen so far.
FS KKR Capital: The Discount Is Not Enough, And Dividend Cut Likely
Before FSK circulated its Q4 report, I issued a bearish piece, realizing my 27% returns and suggesting investors to avoid the investment. Since then the share price has increased by 5%, but the underlying fundamentals have become worse. Plus, Q4 was a miss. In this article I explain in more details why I still recommend investors to think twice before deploying capital in FSK stock.
Assura board accepts £1.6bn offer from KKR consortium
Assura Group (LSE:AGR) told investors it "would be minded" to accept a £1.6 billion takeover bid from KKR and Stonepeak Partners. Having rejected several previous offers, the board of the UK healthcare property investor said the consortium has now upped its bid to a potential cash offer of 49.4p per share.
UK's Assura in talks with KKR consortium for $2.08 billion offer
British healthcare real estate investment trust Assura on Monday said it will likely consider a 1.61 billion pounds ($2.08 billion) offer from KKR and Stonepeak Partners, after rejecting four previous offers from another KKR-led consortium.
KKR: Overreaction To Modest Dilution Creates Opportunity (Rating Upgrade)
KKR shares have dropped over 25% in 2025, but are still up 21% from last year due to strong financial results. KKR's issuance of mandatory convertible preferred shares aims to raise $1.5 billion, diluting shareholders by about 1% to invest in Strategic Holdings. Strategic Holdings' aggressive growth targets add complexity and potential volatility to KKR's earnings, raising concerns among investors.
CapEx slow down in Mexico is manifesting itself right now, says KKR's Henry McVey
Henry McVey, KKR head of the global macro, balance sheet and risk teams, joins 'The Exchange' to discuss the facts on tariffs, where businesses are moving production, and if the market's reaction makes sense.
FS KKR: Q4 Earnings Warrant Caution (Rating Downgrade)
FS KKR Capital is downgraded to a hold due to declining NAV, weakening net investment income, and a shrinking total asset value. FSK's portfolio strategy includes a diverse $13.5B portfolio with 63.8% in senior secured debt, benefiting from high-interest rates. Although non-accruals haven't substantially increased, we can see an uptick in PIK interest income.
UK's Thames Water asks for bid detail from KKR and Castle Water, Bloomberg News reports
Britain's Thames Water has asked KKR and Castle Water to provide more detail on their equity bids, Bloomberg News reported on Tuesday, citing people familiar with the matter.
Exclusive: KKR, Fountainvest and PAG among those eyeing Starbucks China stake, sources say
KKR & Co , Fountainvest Partners and PAG are among buyout firms interested in acquiring a stake in Starbucks' China business, four sources said, as the U.S. coffee chain looks to revive flagging sales in its second-largest market.
